The Utility of Electronic Inhaler Monitoring in COPD Management: Promises and Challenges.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
06 2020
Historique:
received: 09 05 2019
revised: 19 12 2019
accepted: 28 12 2019
pubmed: 26 1 2020
medline: 18 5 2021
entrez: 26 1 2020
Statut: ppublish

Résumé

COPD is a common respiratory disorder that poses a major health-care burden with societal and financial ramifications. Although effective inhaled therapies are available, nonadherence is common among patients with COPD and potentially contributes to the burden of this disease. Electronic inhaler monitoring (EIM) is a novel modality that enables real-time assessment of adherence to inhaled therapy and informs the assessment of treatment effectiveness. EIM can be combined with physician feedback, automated audiovisual reminders, and text messaging to bolster adherence. Clinical studies have suggested that EIM can diagnose nonadherence, improve adherence, and predict exacerbations. Using an EIM-guided protocol has the potential to avoid treatment escalation in the nonadherent. Coupling EIM to behavioral intervention is an area of ongoing research with mixed results, with some studies showing benefit and others showing minimal or no significant change in clinical outcomes. Further investigation is necessary to understand the incremental benefits of EIM features, delineate optimal program implementation, and target patient populations that would benefit the most from monitoring.

Identifiants

pubmed: 31981565
pii: S0012-3692(20)30116-1
doi: 10.1016/j.chest.2019.12.034
pii:
doi:

Substances chimiques

Bronchodilator Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1466-1477

Informations de copyright

Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Amy H Attaway (AH)

Respiratory Institute, Cleveland Clinic, Cleveland, OH. Electronic address: attawaa@ccf.org.

Khaled Alshabani (K)

Respiratory Institute, Cleveland Clinic, Cleveland, OH.

Bruce Bender (B)

National Jewish Health, Denver, CO.

Umur S Hatipoğlu (US)

Respiratory Institute, Cleveland Clinic, Cleveland, OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH